Diabetic nephropathy

Themis Zelmanovitz, Fernando Gerchman, Amely Ps Balthazar, Fúlvio Cs Thomazelli, Jorge D Matos, Luís H Canani, Themis Zelmanovitz, Fernando Gerchman, Amely Ps Balthazar, Fúlvio Cs Thomazelli, Jorge D Matos, Luís H Canani

Abstract

Diabetic nephropathy is the leading cause of chronic renal disease and a major cause of cardiovascular mortality. Diabetic nephropathy has been categorized into stages: microalbuminuria and macroalbuminuria. The cut-off values of micro- and macroalbuminuria are arbitrary and their values have been questioned. Subjects in the upper-normal range of albuminuria seem to be at high risk of progression to micro- or macroalbuminuria and they also had a higher blood pressure than normoalbuminuric subjects in the lower normoalbuminuria range. Diabetic nephropathy screening is made by measuring albumin in spot urine. If abnormal, it should be confirmed in two out three samples collected in a three to six-months interval. Additionally, it is recommended that glomerular filtration rate be routinely estimated for appropriate screening of nephropathy, because some patients present a decreased glomerular filtration rate when urine albumin values are in the normal range. The two main risk factors for diabetic nephropathy are hyperglycemia and arterial hypertension, but the genetic susceptibility in both type 1 and type 2 diabetes is of great importance. Other risk factors are smoking, dyslipidemia, proteinuria, glomerular hyperfiltration and dietary factors. Nephropathy is pathologically characterized in individuals with type 1 diabetes by thickening of glomerular and tubular basal membranes, with progressive mesangial expansion (diffuse or nodular) leading to progressive reduction of glomerular filtration surface. Concurrent interstitial morphological alterations and hyalinization of afferent and efferent glomerular arterioles also occur. Podocytes abnormalities also appear to be involved in the glomerulosclerosis process. In patients with type 2 diabetes, renal lesions are heterogeneous and more complex than in individuals with type 1 diabetes. Treatment of diabetic nephropathy is based on a multiple risk factor approach, and the goal is retarding the development or progression of the disease and to decrease the subject's increased risk of cardiovascular disease. Achieving the best metabolic control, treating hypertension (<130/80 mmHg) and dyslipidemia (LDL cholesterol <100 mg/dl), using drugs that block the renin-angiotensin-aldosterone system, are effective strategies for preventing the development of microalbuminuria, delaying the progression to more advanced stages of nephropathy and reducing cardiovascular mortality in patients with diabetes.

References

    1. U.S. Renal Data System, USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2003
    1. Bruno RM, Gross JL. Prognostic factors in Brazilian diabetic patients starting dialysis: a 3.6-year follow-up study. J Diabetes Complications. 2000;14:266–271. doi: 10.1016/S1056-8727(00)00118-5.
    1. Valmadrid CT, Klein R, Moss SE, Klein BE. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med. 2000;160:1093–1100. doi: 10.1001/archinte.160.8.1093.
    1. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med. 1984;311:89–93.
    1. Parving HH, Oxenboll B, Svendsen PA, Christiansen JS, Andersen AR. Early detection of patients at risk of developing diabetic nephropathy. A longitudinal study of urinary albumin excretion. Acta Endocrinol (Copenh) 1982;100:550–555.
    1. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin- dependent diabetes mellitus. Lancet. 1982;1:1430–1432. doi: 10.1016/S0140-6736(82)92450-3.
    1. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;310:356–360.
    1. MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, Smith TJ, McNeil KJ, Jerums G. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care. 2004;27:195–200. doi: 10.2337/diacare.27.1.195.
    1. Caramori ML, Fioretto P, Mauer M. Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions. Diabetes. 2003;52:1036–1040. doi: 10.2337/diabetes.52.4.1036.
    1. Kramer CK, Leitao CB, Pinto LC, Silveiro SP, Gross JL, Canani LH. Clinical and laboratory profile of patients with type 2 diabetes with low glomerular filtration rate and normoalbuminuria. Diabetes Care. 2007;30:1998–2000. doi: 10.2337/dc07-0387.
    1. Perkins BA, Krolewski AS. Early nephropathy in type 1 diabetes: the importance of early renal function decline. Curr Opin Nephrol Hypertens. 2009;18:233–240. doi: 10.1097/MNH.0b013e3283293db1.
    1. Young BA, Maynard C, Boyko EJ. Racial differences in diabetic nephropathy, cardiovascular disease, and mortality in a national population of veterans. Diabetes Care. 2003;26:2392–2399. doi: 10.2337/diacare.26.8.2392.
    1. Gerchman F, Zanatta CM, Burttet LM, Picon PX, Lisboa HR, Silveiro SP, Gross JL, Canani LH. Vascular complications of black patients with type 2 diabetes mellitus in Southern Brazil. Braz J Med Biol Res. 2008;41:668–673.
    1. American Diabetes Association Nephropathy in Diabetes. Diabetes Care. 2004;27:S79–83. doi: 10.2337/diacare.27.2007.S79.
    1. Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes. 2000;49:1399–1408. doi: 10.2337/diabetes.49.9.1399.
    1. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. N Engl J Med. 2003;348:2285–2293. doi: 10.1056/NEJMoa021835.
    1. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med. 1997;157:1413–1418. doi: 10.1001/archinte.157.13.1413.
    1. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes. 2002;51:1157–1165. doi: 10.2337/diabetes.51.4.1157.
    1. Forsblom CM, Groop PH, Ekstrand A, Totterman KJ, Sane T, Saloranta C, Groop L. Predictors of progression from normoalbuminuria to microalbuminuria in NIDDM. Diabetes Care. 1998;21:1932–1938. doi: 10.2337/diacare.21.11.1932.
    1. Murussi M, Baglio P, Gross JL, Silveiro SP. Risk factors for microalbuminuria and macroalbuminuria in type 2 diabetic patients: a 9-year follow-up study. Diabetes Care. 2002;25:1101–1103. doi: 10.2337/diacare.25.6.1101.
    1. Predictors of the development of microalbuminuria in patients with Type 1 diabetes mellitus: a seven-year prospective study. The Microalbuminuria Collaborative Study Group. Diabet Med. 1999;16:918–925. doi: 10.1046/j.1464-5491.1999.00182.x.
    1. Leitao CB, Canani LH, Polson PB, Molon MP, Pinotti AF, Gross JL. Urinary albumin excretion rate is associated with increased ambulatory blood pressure in normoalbuminuric type 2 diabetic patients. Diabetes Care. 2005;28:1724–1729. doi: 10.2337/diacare.28.7.1724.
    1. Viberti GC, Bilous RW, Mackintosh D, Keen H. Monitoring glomerular function in diabetic nephropathy. A prospective study. Am J Med. 1983;74:256–264. doi: 10.1016/0002-9343(83)90624-1.
    1. Gall MA, Nielsen FS, Smidt UM, Parving HH. The course of kidney function in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy. Diabetologia. 1993;36:1071–1078. doi: 10.1007/BF02374501.
    1. Friedman R, Gross JL. Evolution of glomerular filtration rate in proteinuric NIDDM patients. Diabetes Care. 1991;14:355–359. doi: 10.2337/diacare.14.5.355.
    1. Nosadini R, Velussi M, Brocco E, Bruseghin M, Abaterusso C, Saller A, Dalla Vestra M, Carraro A, Bortoloso E, Sambataro M, Barzon I, Frigato F, Muollo B, Chiesura-Corona M, Pacini G, Baggio B, Piarulli F, Sfriso A, Fioretto P. Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate. Diabetes. 2000;49:476–484. doi: 10.2337/diabetes.49.3.476.
    1. Standards of medical care in diabetes--2009. Diabetes Care. 2009;32:S13–61.
    1. Zelmanovitz T, Gross JL, Oliveira JR, Paggi A, Tatsch M, Azevedo MJ. The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. Diabetes Care. 1997;20:516–519. doi: 10.2337/diacare.20.4.516.
    1. Incerti J, Zelmanovitz T, Camargo JL, Gross JL, de Azevedo MJ. Evaluation of tests for microalbuminuria screening in patients with diabetes. Nephrol Dial Transplant. 2005;20:2402–2407. doi: 10.1093/ndt/gfi074.
    1. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28:164–176. doi: 10.2337/diacare.28.1.164.
    1. Mogensen CE, Vestbo E, Poulsen PL, Christiansen C, Damsgaard EM, Eiskjaer H, Froland A, Hansen KW, Nielsen S, Pedersen MM. Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. Diabetes Care. 1995;18:572–581.
    1. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) Kidney Int. 2005;67:2089–2100. doi: 10.1111/j.1523-1755.2005.00365.x.
    1. Beetham R, Cattell WR. Proteinuria: pathophysiology, significance and recommendations for measurement in clinical practice. Ann Clin Biochem. 1993;30:425–434.
    1. Kramer CK, Camargo J, Ricardo ED, Almeida FK, Canani LH, Gross JL, Azevedo MJ. Does bacteriuria interfere with albuminuria measurements of patients with diabetes? Nephrol Dial Transplant. 2009;24:1193–1196. doi: 10.1093/ndt/gfn629.
    1. Comper WD, Osicka TM, Jerums G. High prevalence of immuno-unreactive intact albumin in urine of diabetic patients. Am J Kidney Dis. 2003;41:336–342. doi: 10.1053/ajkd.2003.50041.
    1. Brinkman JW, Bakker SJ, Gansevoort RT, Hillege HL, Kema IP, Gans RO, de Jong PE, de Zeeuw D. Which method for quantifying urinary albumin excretion gives what outcome? A comparison of immunonephelometry with HPLC. Kidney Int Suppl. 2004:S69–75. doi: 10.1111/j.1523-1755.2004.09219.x.
    1. Comper WD, Osicka TM, Clark M, MacIsaac RJ, Jerums G. Earlier detection of microalbuminuria in diabetic patients using a new urinary albumin assay. Kidney Int. 2004;65:1850–1855. doi: 10.1111/j.1523-1755.2004.00585.x.
    1. Comper WD, Osicka TM. Detection of urinary albumin. Adv Chronic Kidney Dis. 2005;12:170–176. doi: 10.1053/j.ackd.2005.01.012.
    1. Jerums G, Premaratne E, Panagiotopoulos S, Clarke S, Power DA, MacIsaac RJ. New and old markers of progression of diabetic nephropathy. Diabetes Res Clin Pract. 2008;82:S30–37. doi: 10.1016/j.diabres.2008.09.032.
    1. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–147.
    1. Granerus G, Aurell M. Reference values for 51Cr-EDTA clearance as a measure of glomerular filtration rate. Scand J Clin Lab Invest. 1981;41:611–616. doi: 10.3109/00365518109090505.
    1. Christensen PK, Larsen S, Horn T, Olsen S, Parving HH. Renal function and structure in albuminuric type 2 diabetic patients without retinopathy. Nephrol Dial Transplant. 2001;16:2337–2347. doi: 10.1093/ndt/16.12.2337.
    1. Mauer M, Fioretto P, Woredekal Y, Friedman EA. Diabetic Nephropathy. In: Schrier RW, editor. Diseases of the Kidney and Urinary Tract. 7. Lippincott Williams & Wilkins; 2001. pp. 2083–2116.
    1. Huang F, Yang Q, Chen L, Tang S, Liu W, Yu X. Renal pathological change in patients with type 2 diabetes is not always diabetic nephropathy: a report of 52 cases. Clin Nephrol. 2007;67:293–297.
    1. Wong TY, Choi PC, Szeto CC, To KF, Tang NL, Chan AW, Li PK, Lai FM. Renal outcome in type 2 diabetic patients with or without coexisting nondiabetic nephropathies. Diabetes Care. 2002;25:900–905. doi: 10.2337/diacare.25.5.900.
    1. Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR. The changing natural history of nephropathy in type I diabetes. Am J Med. 1985;78:785–794. doi: 10.1016/0002-9343(85)90284-0.
    1. Krolewski AS. Genetics of diabetic nephropathy: evidence for major and minor gene effects. Kidney Int. 1999;55:1582–1596. doi: 10.1046/j.1523-1755.1999.00371.x.
    1. Krolewski AS, Ng DP, Canani LH, Warram JH. Genetics of diabetic nephropathy: how far are we from finding susceptibility genes? Adv Nephrol Necker Hosp. 2001;31:295–315.
    1. Quinn M, Angelico MC, Warram JH, Krolewski AS. Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia. 1996;39:940–945. doi: 10.1007/BF00403913.
    1. Pettitt DJ, Saad MF, Bennett PH, Nelson RG, Knowler WC. Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1990;33:438–443. doi: 10.1007/BF00404096.
    1. Freedman BI, Tuttle AB, Spray BJ. Familial predisposition to nephropathy in African-Americans with non-insulin-dependent diabetes mellitus. Am J Kidney Dis. 1995;25:710–713. doi: 10.1016/0272-6386(95)90546-4.
    1. Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes. 1997;46:1829–1839. doi: 10.2337/diabetes.46.11.1829.
    1. Canani LH, Gerchman F, Gross JL. Familial clustering of diabetic nephropathy in Brazilian type 2 diabetic patients. Diabetes. 1999;48:909–913. doi: 10.2337/diabetes.48.4.909.
    1. Placha G, Canani LH, Warram JH, Krolewski AS. Evidence for different susceptibility genes for proteinuria and ESRD in type 2 diabetes. Adv Chronic Kidney Dis. 2005;12:155–169. doi: 10.1053/j.ackd.2005.02.002.
    1. Gall MA, Hougaard P, Borch-Johnsen K, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ. 1997;314:783–788.
    1. Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med. 1998;158:998–1004. doi: 10.1001/archinte.158.9.998.
    1. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–412. doi: 10.1136/bmj.321.7258.405.
    1. Alaveras AE, Thomas SM, Sagriotis A, Viberti GC. Promoters of progression of diabetic nephropathy: the relative roles of blood glucose and blood pressure control. Nephrol Dial Transplant. 1997;12:71–74.
    1. Hovind P, Rossing P, Tarnow L, Parving HH. Smoking and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care. 2003;26:911–916. doi: 10.2337/diacare.26.3.911.
    1. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med. 1998;339:69–75. doi: 10.1056/NEJM199807093390202.
    1. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572. doi: 10.1056/NEJMicm066227.
    1. Park JY, Kim HK, Chung YE, Kim SW, Hong SK, Lee KU. Incidence and determinants of microalbuminuria in Koreans with type 2 diabetes. Diabetes Care. 1998;21:530–534. doi: 10.2337/diacare.21.4.530.
    1. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412–419. doi: 10.1136/bmj.321.7258.412.
    1. Sawicki PT, Didjurgeit U, Muhlhauser I, Bender R, Heinemann L, Berger M. Smoking is associated with progression of diabetic nephropathy. Diabetes Care. 1994;17:126–131. doi: 10.2337/diacare.17.2.126.
    1. Smulders YM, Rakic M, Stehouwer CD, Weijers RN, Slaats EH, Silberbusch J. Determinants of progression of microalbuminuria in patients with NIDDM. A prospective study. Diabetes Care. 1997;20:999–1005. doi: 10.2337/diacare.20.6.999.
    1. Chaturvedi N, Fuller JH, Taskinen MR. Differing associations of lipid and lipoprotein disturbances with the macrovascular and microvascular complications of type 1 diabetes. Diabetes Care. 2001;24:2071–2077. doi: 10.2337/diacare.24.12.2071.
    1. Jenkins AJ, Lyons TJ, Zheng D, Otvos JD, Lackland DT, McGee D, Garvey WT, Klein RL. Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy. Kidney Int. 2003;64:817–828. doi: 10.1046/j.1523-1755.2003.00164.x.
    1. Mulec H, Johnsen SA, Wiklund O, Bjorck S. Cholesterol: a renal risk factor in diabetic nephropathy? Am J Kidney Dis. 1993;22:196–201.
    1. Ruggenenti P, Remuzzi G. Nephropathy of type-2 diabetes mellitus. J Am Soc Nephrol. 1998;9:2157–2169.
    1. Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int. 1997;51:2–15. doi: 10.1038/ki.1997.2.
    1. Caramori ML, Gross JL, Pecis M, de Azevedo MJ. Glomerular filtration rate, urinary albumin excretion rate, and blood pressure changes in normoalbuminuric normotensive type 1 diabetic patients: an 8-year follow-up study. Diabetes Care. 1999;22:1512–1516. doi: 10.2337/diacare.22.9.1512.
    1. Silveiro SP, Friedman R, Gross JL. Glomerular hyperfiltration in NIDDM patients without overt proteinuria. Diabetes Care. 1993;16:115–119. doi: 10.2337/diacare.16.1.115.
    1. Brenner BM, Lawler EV, Mackenzie HS. The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int. 1996;49:1774–1777. doi: 10.1038/ki.1996.265.
    1. Dahlquist G, Stattin EL, Rudberg S. Urinary albumin excretion rate and glomerular filtration rate in the prediction of diabetic nephropathy; a long-term follow-up study of childhood onset type-1 diabetic patients. Nephrol Dial Transplant. 2001;16:1382–1386. doi: 10.1093/ndt/16.7.1382.
    1. Silveiro SP, da Costa LA, Beck MO, Gross JL. Urinary albumin excretion rate and glomerular filtration rate in single-kidney type 2 diabetic patients. Diabetes Care. 1998;21:1521–1524. doi: 10.2337/diacare.21.9.1521.
    1. Ficociello LH, Perkins BA, Roshan B, Weinberg JM, Aschengrau A, Warram JH, Krolewski AS. Renal hyperfiltration and the development of microalbuminuria in type 1 diabetes. Diabetes Care. 2009;32:889–893. doi: 10.2337/dc08-1560.
    1. Chang S, Caramori ML, Moriya R, Mauer M. Having one kidney does not accelerate the rate of development of diabetic nephropathy lesions in type 1 diabetic patients. Diabetes. 2008;57:1707–1711. doi: 10.2337/db07-1610.
    1. Yip JW, Jones SL, Wiseman MJ, Hill C, Viberti G. Glomerular hyperfiltration in the prediction of nephropathy in IDDM: a 10-year follow-up study. Diabetes. 1996;45:1729–1733. doi: 10.2337/diabetes.45.12.1729.
    1. Toeller M, Buyken A, Heitkamp G, Bramswig S, Mann J, Milne R, Gries FA, Keen H. Protein intake and urinary albumin excretion rates in the EURODIAB IDDM Complications Study. Diabetologia. 1997;40:1219–1226. doi: 10.1007/s001250050810.
    1. Mollsten AV, Dahlquist GG, Stattin EL, Rudberg S. Higher intakes of fish protein are related to a lower risk of microalbuminuria in young Swedish type 1 diabetic patients. Diabetes Care. 2001;24:805–810. doi: 10.2337/diacare.24.5.805.
    1. Pecis M, de Azevedo MJ, Gross JL. Chicken and fish diet reduces glomerular hyperfiltration in IDDM patients. Diabetes Care. 1994;17:665–672. doi: 10.2337/diacare.17.7.665.
    1. Riley MD, Dwyer T. Microalbuminuria is positively associated with usual dietary saturated fat intake and negatively associated with usual dietary protein intake in people with insulin-dependent diabetes mellitus. Am J Clin Nutr. 1998;67:50–57.
    1. Almeida JC, Zelmanovitz T, Vaz JS, Steemburgo T, Perassolo MS, Gross JL, Azevedo MJ. Sources of protein and polyunsaturated fatty acids of the diet and microalbuminuria in type 2 diabetes mellitus. J Am Coll Nutr. 2008;27:528–537.
    1. Cardenas C, Bordiu E, Bagazgoitia J, Calle-Pascual AL. Polyunsaturated fatty acid consumption may play a role in the onset and regression of microalbuminuria in well-controlled type 1 and type 2 diabetic people: a 7-year, prospective, population-based, observational multicenter study. Diabetes Care. 2004;27:1454–1457. doi: 10.2337/diacare.27.6.1454.
    1. Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med. 1989;320:1161–1165.
    1. Krolewski AS, Poznik GD, Placha G, Canani L, Dunn J, Walker W, Smiles A, Krolewski B, Fogarty DG, Moczulski D, Araki S, Makita Y, Ng DP, Rogus J, Duggirala R, Rich SS, Warram JH. A genome-wide linkage scan for genes controlling variation in urinary albumin excretion in type II diabetes. Kidney Int. 2006;69:129–136. doi: 10.1038/sj.ki.5000023.
    1. Pezzolesi MG, Poznik GD, Mychaleckyj JC, Paterson AD, Barati MT, Klein JB, Ng DP, Placha G, Canani LH, Bochenski J, Waggott D, Merchant ML, Krolewski B, Mirea L, Wanic K, Katavetin P, Kure M, Wolkow P, Dunn JS, Smiles A, Walker WH, Boright AP, Bull SB, Doria A, Rogus JJ, Rich SS, Warram JH, Krolewski AS. Genome-wide Association Scan for Diabetic Nephropathy Susceptibility Genes in Type 1 Diabetes Mellitus. Diabetes. 2009.
    1. Rogus JJ, Poznik GD, Pezzolesi MG, Smiles AM, Dunn J, Walker W, Wanic K, Moczulski D, Canani L, Araki S, Makita Y, Warram JH, Krolewski AS. High-density single nucleotide polymorphism genome-wide linkage scan for susceptibility genes for diabetic nephropathy in type 1 diabetes: discordant sibpair approach. Diabetes. 2008;57:2519–2526. doi: 10.2337/db07-1086.
    1. Gross JL, Zelmanovitz T, Moulin CC, De Mello V, Perassolo M, Leitao C, Hoefel A, Paggi A, Azevedo MJ. Effect of a chicken-based diet on renal function and lipid profile in patients with type 2 diabetes: a randomized crossover trial. Diabetes Care. 2002;25:645–651. doi: 10.2337/diacare.25.4.645.
    1. Boright AP, Paterson AD, Mirea L, Bull SB, Mowjoodi A, Scherer SW, Zinman B. Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes: the DCCT/EDIC Genetics Study. Diabetes. 2005;54:1238–1244. doi: 10.2337/diabetes.54.4.1238.
    1. Brosius FC., 3rd New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy. Rev Endocr Metab Disord. 2008;9:245–254. doi: 10.1007/s11154-008-9100-6.
    1. Kramer CK, Leitao CB, Pinto LC, Bolson P, Boza J, Silveiro SP, Gross JL, Canani LH. Risk Factors for Micro and Macrovascular Disease in black and white Patients with Type 2 Diabetes Mellitus. Revista Associação Médica Brasileira. 2009.
    1. Fioretto P, Caramori ML, Mauer M. The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture. Diabetologia. 2007;51:1347–1355. doi: 10.1007/s00125-008-1051-7.
    1. Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab. 2008;4:444–452. doi: 10.1038/ncpendmet0894.
    1. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes. 2005;54:1626–1634. doi: 10.2337/diabetes.54.6.1626.
    1. Henegar JR, Bigler SA, Henegar LK, Tyagi SC, Hall JE. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol. 2001;12:1211–1217.
    1. Chagnac A, Weinstein T, Herman M, Hirsh J, Gafter U, Ori Y. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol. 2003;14:1480–1486. doi: 10.1097/01.ASN.0000068462.38661.89.
    1. Zanatta CM, Gerchman F, Burttet L, Nabinger G, Jacques-Silva MC, Canani LH, Gross JL. Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2008;80:299–304. doi: 10.1016/j.diabres.2007.12.024.
    1. Sharma K, Eltayeb BO, McGowan TA, Dunn SR, Alzahabi B, Rohde R, Ziyadeh FN, Lewis EJ. Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis. 1999;34:818–823. doi: 10.1016/S0272-6386(99)70037-5.
    1. Hogan M, Cerami A, Bucala R. Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus. J Clin Invest. 1992;90:1110–1115. doi: 10.1172/JCI115928.
    1. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med. 1991;325:836–842.
    1. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet. 1998;352:213–219. doi: 10.1016/S0140-6736(98)01346-4.
    1. Yamagishi S, Fukami K, Ueda S, Okuda S. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr Drug Targets. 2007;8:952–959. doi: 10.2174/138945007781386884.
    1. Yamagishi S, Matsui T, Ueda S, Nakamura K, Imaizumi T. Advanced glycation end products (AGEs) and cardiovascular disease (CVD) in diabetes. Cardiovasc Hematol Agents Med Chem. 2007;5:236–240. doi: 10.2174/187152507781058681.
    1. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005;366:2026–2033. doi: 10.1016/S0140-6736(05)67814-2.
    1. Sarafidis PA, Stafylas PC, Kanaki AI, Lasaridis AN. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis. Am J Hypertens. 2008;21:922–929. doi: 10.1038/ajh.2008.206.
    1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977–986. doi: 10.1056/NEJM199309303291401.
    1. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290:2159–2167. doi: 10.1001/jama.290.16.2159.
    1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837–853. doi: 10.1016/S0140-6736(98)07019-6.
    1. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23:B21–29.
    1. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589. doi: 10.1056/NEJMoa0806470.
    1. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int. 1995;47:1703–1720. doi: 10.1038/ki.1995.236.
    1. Intensive therapy and progression to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria. Microalbuminuria Collaborative Study Group, United Kingdom. BMJ. 1995;311:973–977.
    1. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–139. doi: 10.1056/NEJMoa0808431.
    1. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703–713.
    1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr, Jones DW, Materson BJ, Oparil S, Wright JT, Jr, Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–2572. doi: 10.1001/jama.289.19.2560.
    1. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755–1762. doi: 10.1016/S0140-6736(98)04311-6.
    1. Mogensen CE. Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes. J Intern Med. 2003;254:45–66. doi: 10.1046/j.1365-2796.2003.01157.x.
    1. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36:646–661.
    1. Vijan S, Hayward RA. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med. 2003;138:593–602.
    1. Bakris GL. A practical approach to achieving recommended blood pressure goals in diabetic patients. Arch Intern Med. 2001;161:2661–2667. doi: 10.1001/archinte.161.22.2661.
    1. Jerums G, Allen TJ, Campbell DJ, Cooper ME, Gilbert RE, Hammond JJ, Raffaele J, Tsalamandris C. Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. Am J Kidney Dis. 2001;37:890–899. doi: 10.1016/S0272-6386(05)80003-4.
    1. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004–1010. doi: 10.1016/S0140-6736(02)08090-X.
    1. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1998;128:982–988.
    1. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355:253–259. doi: 10.1016/S0140-6736(99)12323-7.
    1. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, Drummond K, Donnelly S, Goodyer P, Gubler MC, Klein R. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009;361:40–51. doi: 10.1056/NEJMoa0808400.
    1. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002;106:672–678. doi: 10.1161/01.CIR.0000024416.33113.0A.
    1. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med. 2001;134:370–379.
    1. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–878. doi: 10.1056/NEJMoa011489.
    1. Parving HH, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet. 1983;1:1175–1179. doi: 10.1016/S0140-6736(83)92462-5.
    1. Rossing P, Hommel E, Smidt UM, Parving HH. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia. 1994;37:511–516. doi: 10.1007/s001250050140.
    1. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995;123:754–762.
    1. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456–1462. doi: 10.1056/NEJM199311113292004.
    1. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869. doi: 10.1056/NEJMoa011161.
    1. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860. doi: 10.1056/NEJMoa011303.
    1. Andersen S, Jacobsen P, Tarnow L, Rossing P, Juhl TR, Parving HH. Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy. Nephrol Dial Transplant. 2003;18:293–297. doi: 10.1093/ndt/18.2.293.
    1. Weinberg MS, Kaperonis N, Bakris GL. How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy? Curr Hypertens Rep. 2003;5:418–425. doi: 10.1007/s11906-003-0088-8.
    1. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000;160:685–693. doi: 10.1001/archinte.160.5.685.
    1. Nicholls AJ. The impact of atherosclerotic renovascular disease on diabetic renal failure. Diabet Med. 2002;19:889–894. doi: 10.1046/j.1464-5491.2002.00813.x.
    1. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321:1440–1444. doi: 10.1136/bmj.321.7274.1440.
    1. Rosner MH, Okusa MD. Combination therapy with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in the treatment of patients with type 2 diabetes mellitus. Arch Intern Med. 2003;163:1025–1029. doi: 10.1001/archinte.163.9.1025.
    1. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsarinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547–553. doi: 10.1016/S0140-6736(08)61236-2.
    1. Fried LF, Duckworth W, Zhang JH, O'Connor T, Brophy M, Emanuele N, Huang GD, McCullough PA, Palevsky PM, Seliger S, Warren SR, Peduzzi P. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D) Clin J Am Soc Nephrol. 2009;4:361–368. doi: 10.2215/CJN.03350708.
    1. Yoneda T, Takeda Y, Usukura M, Oda N, Takata H, Yamamoto Y, Karashima S, Yamagishi M. Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus. Am J Hypertens. 2007;20:1329–1333. doi: 10.1016/j.amjhyper.2007.09.001.
    1. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension. 2003;41:64–68. doi: 10.1161/01.HYP.0000044937.95080.E9.
    1. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4:542–551. doi: 10.2215/CJN.04750908.
    1. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433–2446. doi: 10.1056/NEJMoa0708379.
    1. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant. 2009;24:1663–1671. doi: 10.1093/ndt/gfn721.
    1. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334:574–579. doi: 10.1056/NEJM199602293340906.
    1. Rachmani R, Slavachevski I, Levi Z, Zadok B, Kedar Y, Ravid M. Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. Eur J Intern Med. 2002;13:428. doi: 10.1016/S0953-6205(02)00131-0.
    1. Shaw JS, Wilmot RL, Kilpatrick ES. Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabet Med. 2007;24:1160–1163. doi: 10.1111/j.1464-5491.2007.02221.x.
    1. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002;287:360–372. doi: 10.1001/jama.287.3.360.
    1. Charpentier G, Riveline JP, Varroud-Vial M. Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab. 2000;26:73–85.
    1. Harrower AD. Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency. Clin Pharmacokinet. 1996;31:111–119. doi: 10.2165/00003088-199631020-00003.
    1. Hasslacher C. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care. 2003;26:886–891. doi: 10.2337/diacare.26.3.886.
    1. Del Prato S, Heine RJ, Keilson L, Guitard C, Shen SG, Emmons RP. Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis. Diabetes Care. 2003;26:2075–2080. doi: 10.2337/diacare.26.7.2075.
    1. Schumacher S, Abbasi I, Weise D, Hatorp V, Sattler K, Sieber J, Hasslacher C. Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. Eur J Clin Pharmacol. 2001;57:147–152. doi: 10.1007/s002280100280.
    1. Nagai T, Imamura M, Iizuka K, Mori M. Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure. Diabetes Res Clin Pract. 2003;59:191–194. doi: 10.1016/S0168-8227(02)00242-5.
    1. Inoue T, Shibahara N, Miyagawa K, Itahana R, Izumi M, Nakanishi T, Takamitsu Y. Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. Clin Nephrol. 2003;60:90–95.
    1. Reuser AJ, Wisselaar HA. An evaluation of the potential side-effects of alpha-glucosidase inhibitors used for the management of diabetes mellitus. Eur J Clin Invest. 1994;24:19–24.
    1. Szeto CC, Li PK. Antiproteinuric and anti-inflammatory effects of thiazolidinedione. Nephrology (Carlton) 2008;13:53–57.
    1. Iglesias P, Diez JJ. Peroxisome proliferator-activated receptor gamma agonists in renal disease. Eur J Endocrinol. 2006;154:613–621. doi: 10.1530/eje.1.02134.
    1. Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens. 2003;17:7–12. doi: 10.1038/sj.jhh.1001444.
    1. Kincaid-Smith P, Fairley KF, Farish S, Best JD, Proietto J. Reduction of proteinuria by rosiglitazone in non-diabetic renal disease. Nephrology (Carlton) 2008;13:58–62.
    1. Pistrosch F, Herbrig K, Kindel B, Passauer J, Fischer S, Gross P. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes. 2005;54:2206–2211. doi: 10.2337/diabetes.54.7.2206.
    1. Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, Strotmeyer ES, Resnick HE, Carbone L, Beamer BA, Park SW, Lane NE, Harris TB, Cummings SR. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab. 2006;91:3349–3354. doi: 10.1210/jc.2005-2226.
    1. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of thiazolidinediones and fracture risk. Arch Intern Med. 2008;168:820–825. doi: 10.1001/archinte.168.8.820.
    1. Scherbaum WA. Do patients with type 2 diabetes on peritoneal dialysis need less insulin if they are given rosiglitazone? Nat Clin Pract Nephrol. 2006;2:312–313. doi: 10.1038/ncpneph0199.
    1. Farkouh ME, Fuster V. Meta-analysis of small trials: proceed with caution. Nat Clin Pract Nephrol. 2008;4:115. doi: 10.1038/ncpcardio1064.
    1. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009;180:32–39.
    1. Bergman AJ, Cote J, Yi B, Marbury T, Swan SK, Smith W, Gottesdiener K, Wagner J, Herman GA. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care. 2007;30:1862–1864. doi: 10.2337/dc06-2545.
    1. Chan JC, Scott R, Arjona Ferreira JC, Sheng D, Gonzalez E, Davies MJ, Stein PP, Kaufman KD, Amatruda JM, Williams-Herman D. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab. 2008;10:545–555. doi: 10.1111/j.1463-1326.2008.00914.x.
    1. Linnebjerg H, Kothare PA, Park S, Mace K, Reddy S, Mitchell M, Lins R. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol. 2007;64:317–327. doi: 10.1111/j.1365-2125.2007.02890.x.
    1. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Intern Med. 1996;124:627–632.
    1. Hansen HP, Tauber-Lassen E, Jensen BR, Parving HH. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int. 2002;62:220–228. doi: 10.1046/j.1523-1755.2002.00421.x.
    1. Pijls LT, de Vries H, van Eijk JT, Donker AJ. Protein restriction, glomerular filtration rate and albuminuria in patients with type 2 diabetes mellitus: a randomized trial. Eur J Clin Nutr. 2002;56:1200–1207. doi: 10.1038/sj.ejcn.1601474.
    1. Pan Y, Guo LL, Jin HM. Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2008;88:660–666.
    1. de Mello VD, Zelmanovitz T, Perassolo MS, Azevedo MJ, Gross JL. Withdrawal of red meat from the usual diet reduces albuminuria and improves serum fatty acid profile in type 2 diabetes patients with macroalbuminuria. Am J Clin Nutr. 2006;83:1032–1038.
    1. de Mello VD, Zelmanovitz T, Azevedo MJ, de Paula TP, Gross JL. Long-term effect of a chicken-based diet versus enalapril on albuminuria in type 2 diabetic patients with microalbuminuria. J Ren Nutr. 2008;18:440–447. doi: 10.1053/j.jrn.2008.04.010.
    1. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Charlton-Menys V, Demicco DA, Fuller JH. Effects of Atorvastatin on Kidney Outcomes and Cardiovascular Disease in Patients With Diabetes: An Analysis From the Collaborative Atorvastatin Diabetes Study (CARDS) Am J Kidney Dis. 2009.
    1. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–393. doi: 10.1056/NEJMoa021778.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit